Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

URGN
UroGen Pharma Ltd.
stock NASDAQ

At Close
May 16, 2025 3:59:30 PM EDT
7.30USD-25.888%(-2.55)9,676,034
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 16, 2025 9:28:30 AM EDT
8.75USD-11.168%(-1.10)35,079
After-hours
May 16, 2025 4:56:30 PM EDT
7.35USD+0.685%(+0.05)22,220
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 18, 2022
10:03AM EST  HC Wainwright & Co. Maintains Buy on UroGen Pharma, Lowers Price Target to $34   Benzinga
Jan 5, 2022
08:00AM EST  UroGen Pharma to Present at Upcoming Conferences   Business Wire
Dec 21, 2021
08:05AM EST  First Patient Dosed In UroGen Pharma'Study Of UGN-102 In Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer   RTTNews
08:05AM EST  UroGen Pharma Announces First Patient Dosed In It's Home Instillation Study Of UGN-102 In Patients With Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer   Benzinga
08:00AM EST  First Patient Dosed in UroGen Pharma's Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)   Business Wire
Dec 3, 2021
08:00AM EST  UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Nov 30, 2021
04:53PM EST  UroGen Pharma Sponsored Study Titled 'Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)' Posted To ClinicalTrials.gov; Study Is Recruiting   Benzinga
Nov 15, 2021
11:11AM EST  UroGen Pharma Q3 EPS $(1.35) Misses $(1.29) Estimate, Sales $11.35M Miss $15.42M Estimate   Benzinga
11:07AM EST  Earnings Scheduled For November 15, 2021   Benzinga
10:37AM EST  The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More   Benzinga
08:12AM EST  UroGen Pharma Q3 Net Loss $30.2 Mln Or $1.35/shr Vs. Loss $28.8 Mln Or $1.31/shr Prior Year   RTTNews
08:00AM EST  UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments   Business Wire
Nov 12, 2021
11:03AM EST  Earnings Preview: UroGen Pharma   Benzinga
Nov 11, 2021
08:00AM EST  UroGen Pharma Announces Upcoming 2021 Conferences   Business Wire
Nov 10, 2021
11:02AM EST  UroGen Pharma Unveils New Phase 3 Development Plan For UGN-102 At Spotlight Event   Benzinga
Nov 1, 2021
08:00AM EDT  UroGen Pharma to Host Virtual Spotlight Event on November 10, 2021   Business Wire
Oct 5, 2021
08:20AM EDT  UroGen Pharma Highlights Results Of Co.'s Phase 2b Study Of UGN-102 In Patients With Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer Published In 'The Journal Of Urology'   Benzinga
08:00AM EDT  The Journal of Urology Publishes Results of UroGen Pharma's Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)   Business Wire
Sep 23, 2021
08:00AM EDT  UroGen Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference   Business Wire
Sep 13, 2021
08:47AM EDT  UroGen Pharma Ltd. (URGN) reported final data from two key trials with investigational agent UGN-102 (mitomycin) for intravesical solution in adult patients with low-grade intermediate risk non-muscle invasive bladder cancer and Jelmyto (mitomycin) for pyelocalyceal solution in adult patients with low-grade upper tract urothelial cancer.   RTTNews
08:45AM EDT  UroGen Pharma Presents Data Showcasing Novel Clinical Data At 2021 American Urological Association Annual Meeting   Benzinga
08:19AM EDT  UroGen Pharma : UGN-102 May Provide Non-surgical Treatment Option For Chronically Relapsing Patients   RTTNews
08:00AM EDT  UroGen Pharma Presents Data Showcasing Novel Clinical Data at 2021 American Urological Association (AUA) Annual Meeting   Business Wire
Sep 10, 2021
08:00AM EDT  UroGen Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference   Business Wire
Sep 3, 2021
08:06AM EDT  UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule   RTTNews
08:00AM EDT  UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 4, 2021
08:13AM EDT  UroGen Pharma Q2 Net Loss $26.2 Mln Or $31.3 Mln Or $1.44/Shr Last Year   RTTNews
08:03AM EDT  UroGen Pharma Q2 EPS $(1.17) Beats $(1.27) Estimate, Sales $13.00M Beat $10.21M Estimate   Benzinga
08:00AM EDT  UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments   Business Wire
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
04:10AM EDT  Earnings Scheduled For August 4, 2021   Benzinga
Aug 2, 2021
08:30AM EDT  Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz)   GlobeNewswire Inc
Aug 1, 2021
11:19AM EDT  The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs   Benzinga
Jul 29, 2021
08:18AM EDT  The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs   Benzinga
Jul 28, 2021
04:00PM EDT  UroGen Reports License, Supply Deal With Neopharm To Pursue Regulatory Approval, Commercialization Of Jelmyto In Israel   Benzinga
04:00PM EDT  UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercialization for Jelmyto(r) in Israel   Business Wire
08:00AM EDT  UroGen Pharma to Report Second Quarter 2021 Financial Results on Wednesday, August 4, 2021   Business Wire
Jul 14, 2021
08:16AM EDT  UroGen Pharma Expects Q2 Net Product Revenue From Jelmyto Sales to Be About $13.0 Mln   RTTNews
08:03AM EDT  UroGen Pharma Affirms Previous FY21 Guidance; Sees Operating Expenses $155M-$165M; Sees Q2 2021 Operating Expenses $33M-$38M   Benzinga
08:00AM EDT  UroGen Pharma Reports Strong Preliminary Jelmyto(r) Sales for Second Quarter 2021   Business Wire
Jul 13, 2021
08:05AM EDT  The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data   Benzinga
Jul 7, 2021
08:00AM EDT  UroGen Pharma to Present at Ladenburg Thalmann Healthcare Conference   Business Wire
Jun 4, 2021
08:21AM EDT  UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)   RTTNews
May 25, 2021
08:00AM EDT  UroGen Pharma Announces June 2021 Conference Schedule   Business Wire
May 21, 2021
12:49PM EDT  Looking Into UroGen Pharma's Return On Capital Employed   Benzinga
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 13, 2021
08:10AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use   Benzinga
07:54AM EDT  UroGen Pharma Q1 Net Loss $25.9 Mln Or $1.17/Shr Vs Loss 37.8 Mln Or $1.79/Shr Last Year   RTTNews
07:41AM EDT  UroGen Pharma Q1 EPS $(1.17) Beats $(1.29) Estimate, Sales $7.50M Miss $9.05M Estimate   Benzinga
07:30AM EDT  UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments   Business Wire
04:15AM EDT  Earnings Scheduled For May 13, 2021   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 6, 2021
08:00AM EDT  UroGen Pharma to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021   Business Wire
Apr 27, 2021
06:34AM EDT  HC Wainwright & Co. Maintains Buy on UroGen Pharma, Lowers Price Target to $50   Benzinga
Mar 18, 2021
11:19AM EDT  UroGen Pharma shares were trading higher after the company reported Q4 sales results.   Benzinga
08:18AM EDT  UroGen Pharma: Q4 Earnings Insights   Benzinga
08:16AM EDT  The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq   Benzinga
08:12AM EDT  UroGen Pharma Q4 Net Loss $30.5 Mln Or $1.38/Shr Vs Loss Of $39.0 Mln Or $1.86/Shr Last Year   RTTNews
08:10AM EDT  UroGen Pharma Q4 EPS $(1.38) Misses $(1.37) Estimate, Sales $7.97M Beat $7.57M Estimate   Benzinga
08:00AM EDT  UroGen Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments   Business Wire
07:34AM EDT  UroGen Pharma Receives $75M Cash Payment From RTW Investments In Return For Tiered Future Payments Based On Worldwide Annual Net Product Sales Of Jelmyto And UGN-102, If Approved   Benzinga
07:33AM EDT  UroGen Pharma Enters Strategic Funding Agreement With RTW Investments, LP And Its Affiliated Entities   RTTNews
07:30AM EDT  UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments   Business Wire
07:07AM EDT  Earnings Scheduled For March 18, 2021   Benzinga
Mar 15, 2021
08:24AM EDT  UroGen Pharma Announces Sponsored Research Agreement With Johns Hopkins University School Of Medicine To 'Expand Immuno-Oncology Pipeline'   Benzinga
08:08AM EDT  UroGen Announces Strategic, Exploratory Immunotherapy Sponsored Research Agreement With Johns Hopkins University   RTTNews
08:00AM EDT  UroGen Pharma Announces Sponsored Research Agreement with the Johns Hopkins University School of Medicine to Expand Immuno-Oncology Pipeline   Business Wire
Mar 14, 2021
08:14AM EDT  Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations   Benzinga
Mar 11, 2021
08:00AM EST  UroGen Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 18, 2021   Business Wire
Mar 5, 2021
08:14AM EST  UroGen Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)   RTTNews
08:00AM EST  UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Feb 23, 2021
08:00AM EST  UroGen Pharma Announces March 2021 Conference Schedule   Business Wire
Jan 13, 2021
08:19AM EST  UroGen Pharma And MD Anderson Collaborate To Advance Investigational Treatment For High-Grade Bladder Cancer   RTTNews
08:01AM EST  UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer   Business Wire
Jan 6, 2021
08:00AM EST  UroGen Pharma to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference   Business Wire
Dec 16, 2020
07:15AM EST  The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal   Benzinga
Dec 4, 2020
08:00AM EST  UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Dec 3, 2020
08:00AM EST  UroGen Pharma Announces Podium Presentation of Final Jelmyto(r) Data From Pivotal OLYMPUS Trial at the Annual Meeting of the Society of Urologic Oncology   Business Wire
Nov 17, 2020
08:07AM EST  UPDATE: UroGen Reports 65% Complete Response Rate At 3 Months, Duration Of Response Estimated 72.5% At Nine Months   Benzinga
08:06AM EST  UroGen Pharma Reports Final Topline Results From OPTIMA II Phase 2b Trial Evaluating Efficacy, Safety Of UGN-102 For Intravesical Solution In Patients With Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer   Benzinga
08:04AM EST  UroGen Pharma Reports Final Topline Results From OPTIMA II Phase 2b Trial Evaluating Efficacy And Safety Of UGN-102   RTTNews
08:00AM EST  Complete and Durable Responses Observed in OPTIMA II Phase 2b Final Results for UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer   Business Wire
Nov 11, 2020
08:14AM EST  UroGen Pharma Reports Centers For Medicare & Medicaid Services Issued Permanent J-Code For Co.'s Jelmyto, Effective Jan. 1, 2021   Benzinga
08:00AM EST  Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for UroGen's Jelmyto(r) Effective January 1, 2021   Business Wire
Nov 10, 2020
08:00AM EST  UroGen Pharma Announces November 2020 Conference Schedule   Business Wire
Nov 9, 2020
08:33AM EST  Recap: UroGen Pharma Q3 Earnings   Benzinga
08:16AM EST  UroGen Pharma Q3 EPS $(1.31) Beats $(1.49) Estimate, Sales $3.46M Beat $3.34M Estimate   Benzinga
08:16AM EST  UroGen Pharma Q3 Net Loss $28.8 Mln Or $1.31 Per Share   RTTNews
08:00AM EST  UroGen Pharma Reports Third Quarter 2020 Financial Results and Recent Corporate Developments   Business Wire
04:13AM EST  Earnings Scheduled For November 9, 2020   Benzinga
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 2, 2020
08:00AM EST  UroGen Pharma to Report Third Quarter 2020 Financial Results on Monday, November 9, 2020   Business Wire
Oct 5, 2020
08:04AM EDT  UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)   Benzinga
Sep 9, 2020
08:00AM EDT  UroGen Pharma Expands Executive Team to Accelerate Platform Innovation and Drive Commercial Growth   Business Wire
Sep 4, 2020
08:08AM EDT  UroGen Pharma Announces Grants Of Inducement Restricted Stock Units To Nineteen New Employees   RTTNews
08:00AM EDT  UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Aug 27, 2020
08:37AM EDT  Biopharmaceutical company UroGen Pharma Ltd. (URGN) said Thursday that the Phase 2 APOLLO clinical trial of a RTGel hydrogel formulation in combination with Botox (onabotulinumtoxinA) intravesical instillation in patients with overactive bladder (OAB) and urinary incontinence did not meet the primary endpoint of the trial.   RTTNews
08:22AM EDT  UroGen Pharma Announces Update On Phase 2 Trial Of RTGel Hydrogel Formulation In Combination With BOTOX Intravesical Instillation For Overactive Bladder, Urinary Incontinence; Trial Did Not Meet Primary Endpoint   Benzinga
08:12AM EDT  UroGen Pharma Says Phase 2 APOLLO Trial Did Not Meet Primary Endpoint   RTTNews
08:00AM EDT  UroGen Pharma Announces Update on the Phase 2 Trial of an RTGel(tm) Hydrogel Formulation in Combination with BOTOX(r) (onabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary Incontinence   Business Wire
Aug 10, 2020
08:15AM EDT  UroGen Pharma Q2 EPS $(1.44) Beats $(1.58) Estimate, Sales $372.00K Beat $260.00K Estimate   Benzinga
08:14AM EDT  UroGen Pharma Q2 Net Loss $31.3 Mln Or $1.44/Shr Vs Loss $22.5 Mln Or $1.08/Shr Last Year   RTTNews
08:00AM EDT  UroGen Pharma Reports Second Quarter 2020 Financial Results and Recent Corporate Developments   Business Wire
04:10AM EDT  Earnings Scheduled For August 10, 2020   Benzinga
Aug 3, 2020
08:00AM EDT  UroGen Pharma to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020   Business Wire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC